Skip to main content
Equibles
SXTP logo

SXTP · 60 Degrees Pharmaceuticals, Inc. · Metrics

Track SXTP — free

Use SXTP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SXTP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.89 -0.03 (-3.49%) At close · Oct 21
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management has evaluated these conditions and its plans to mitigate them and concluded that, collectively, such plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern for at least one year after the date these consolidated condensed financial statements are issued.”
View the 10-Q filed Aug 14, 2026
Market Cap
$3.24M
Shares
3.52M
Volume · Oct 21 24.69K Avg daily vol (3M) 130.14K

SXTP metrics

65 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.89
Market cap
$3.24M

Price action

20 metrics
Price change (1W)
+2.5%
Price change (30D)
-8.7%
Price change (3M)
-41.3%
Price change (6M)
-47.0%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
218.5%
Annualized volatility (3M)
95.4%
Beta
2.3
RSI (14D)
43.0
Price vs SMA 50
-12.4%
Price vs SMA 200
—
Avg volume (3M)
130,090
Relative volume
0.3
Average dollar volume
$152,546

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
3.52M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1.8×
reciprocal yield 54.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
2.6×
reciprocal yield 38.2%
P / book
1.1
reciprocal yield 89.8%
FCF yield
-305.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-278.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
0.7×
reciprocal yield 141.8%
EV / revenue historical average (5Y)
0.7×
reciprocal yield 141.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
19.4%
Operating margin
-774.8%
Trailing 12 months
Net margin
-729.8%
Gross profit (TTM)
$215,790
Operating profit (TTM)
−$8.61M
Net income (TTM)
−$8.11M
Trailing 12 months
Diluted EPS (TTM)
$-2.65
FCF margin
-800.6%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$28.47

Growth

11 metrics
Revenue growth YoY
+106.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.11M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+620.7%
Year over year · more shares
Revenue CAGR (3Y)
+65.2%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-310.1%
Return on assets
-189.3%
Debt / equity
0.1
Current ratio
2.3
EBITDA (TTM)
−$8.55M
Free cash flow (TTM)
−$8.89M
Quick ratio
1.8
Interest coverage
-1,134.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$872,576
Latest balance sheet
Cash & equivalents
$1.02M
Total assets
$4.28M
Total debt
$150,030

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$8.77M
Capital expenditures (TTM)
$119,880
R&D (TTM)
$2.38M
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
214.5%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
12
13F filer change QoQ
-3
Institutional ownership
21.5%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
10.8%
Active holders' share change QoQ
+88.0%
Holder tenure
2.3
Price vs estimated holder cost
+8.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.3%

Short interest

3 metrics
Short interest
3.8%
Latest settlement · 1.6 days to cover
Days to cover
1.6d
Short-squeeze score
43 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1946563 CUSIP 83006G500 13F (30d) 1 filings 1 filers Visit website Investor relations